In light of this challenge, our investigation into the interaction of PRMT6 with JAK2 to activate the STAT3 pathway (Fig. 6) led us to consider PRMT6 inhibitors as a potentially effective approach for cancer treatment. Here, JAK2 is linked to cancer.